Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04668521 · ClinicalTrials.gov registry record
Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection
A clinical trial, sponsored by Aspira Women's Health.
- Terminated
- Registry status
- 215
- Enrollment target
NCT04668521: Clinical Trial study, sponsored by Aspira Women's Health.
NCT04668521 is a clinical trial that was terminated before completion, run by Aspira Women's Health. The registered enrollment target is 215 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04668521 was terminated before completion, sponsored by Aspira Women's Health.
- TERMINATED
- Registry status
- 215 participants
- Enrollment target
Study Summary
The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.
Primary Outcome
Identify the molecular key driver of Ovarian cancer and develop a diagnostic test for early Ovarian cancer detection
Interventions
- OTHER OVA360
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2020-05-04 |
| Est. Completion | 2023-12-15 |
Why NCT04668521 stopped before completion
NCT04668521 is an observational study that tracks outcomes without assigning an intervention. The registered 215 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which OVA360 is the first listed.
NCT04668521 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04668521 about?
NCT04668521 is a clinical study titled "Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection". The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.
What is the current status of trial NCT04668521?
This trial is currently terminated. The enrollment target is 215 participants. The study started on 2020-05-04. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT04668521?
The interventions under investigation include: OVA360 (OTHER).
Who is sponsoring clinical trial NCT04668521?
This trial is sponsored by Aspira Women's Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05134012 · 215 participants · Phase 3
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
- NCT05169970 · 215 participants · Phase 2
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
- NCT05197270 · 215 participants · Phase 1
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- NCT05230199 · 215 participants · NA
Sensory Optimization of the Hospital Environment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI